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Abstract
Background: Incidental CT findings may provide an opportunity for early detection of chronic obstructive pulmonary
disease (COPD), which may prove important in CT-based lung cancer screening setting. We aimed to determine the
diagnostic performance of human observers to visually evaluate COPD presence on CT images, in comparison to automated
evaluation using quantitative CT measures.
Methods: This study was approved by the Dutch Ministry of Health and the institutional review board. All participants
provided written informed consent. We studied 266 heavy smokers enrolled in a lung cancer screening trial. All subjects
underwent volumetric inspiratory and expiratory chest computed tomography (CT). Pulmonary function testing was used as
the reference standard for COPD. We evaluated the diagnostic performance of eight observers and one automated model
based on quantitative CT measures.
Results: The prevalence of COPD in the study population was 44% (118/266), of whom 62% (73/118) had mild disease. The
diagnostic accuracy was 74.1% in the automated evaluation, and ranged between 58.3% and 74.3% for the visual evaluation
of CT images. The positive predictive value was 74.3% in the automated evaluation, and ranged between 52.9% and 74.7%
for the visual evaluation. Interobserver variation was substantial, even within the subgroup of experienced observers.
Agreement within observers yielded kappa values between 0.28 and 0.68, regardless of the level of expertise. The
agreement between the observers and the automated CT model showed kappa values of 0.12–0.35.
Conclusions: Visual evaluation of COPD presence on chest CT images provides at best modest accuracy and is associated
with substantial interobserver variation. Automated evaluation of COPD subjects using quantitative CT measures appears
superior to visual evaluation by human observers.
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Introduction
Emphysema and airways disease are common incidental
findings on computed tomography (CT) performed for other
reasons, offering the potential to identify subjects with undetected
chronic obstructive pulmonary disease (COPD) [1]. COPD is one
of the leading causes of death [2,3], and is expected to account for
one in every 25 deaths in the developed world [2]. The disease is
predominantly caused by tobacco exposure and is characterized
by chronic airflow obstruction caused by emphysema and airways
disease [4]. Since early smoking cessation prevents COPD disease
progression [5,6] and evidence suggests that early intervention
improves outcome [7,8], early diagnosis is crucial in managing this
disease [9,10]. Unfortunately, symptoms occur late in course of the
disease and early stages are substantially underdiagnosed [11,12].
Additionally, COPD is a predictor of cardiovascular mortality [13]
and lung cancer [14,15]. Given these facts, and given that chest
imaging is among the most commonly ordered radiological
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examinations, often ordered by non-pulmonary specialists in
patients with an unknown COPD status, there has been
considerable interest in the use of chest imaging to identify
subjects with COPD. However, the general conclusion is that
conventional chest radiography is insensitive in identifying mild to
moderate COPD-related abnormalities [16–19]. Contrarily,
COPD-related abnormalities (ie. airways disease and emphysema)
are probably more readily detectable on chest CT as compared to
conventional radiography. The Lung Screening Study supports
this superior accuracy by showing that chest CT depicted 2.5 times
more COPD-related changes compared to chest radiography [20].
Recently, it has been reported that using an automated CT
model based on quantitative measures of emphysema and air
trapping, identification of COPD subjects in a lung cancer
screening setting was feasible with reasonable accuracy [21].
However, the reliability and accuracy of human observers to
visually evaluate COPD presence on CT images is unknown.
Therefore, we aimed to determine the diagnostic performance of
human observers with various levels of expertise to visually
evaluate COPD presence on CT images, and compare this to the
performance of automated evaluation based on quantitative CT
measures.
Methods
Ethics statement
This study was performed within the setting of the population-
based Dutch Belgian Lung Cancer Screening Trial (NELSON-
trial; ISRCTN63545820) [22], which was approved by the Dutch
Ministry of Health and by the local ethical review board (‘Medisch
Ethische Toetsingcommissie University Medical Center Utrecht’).
To study COPD, expiratory CT acquisition was added to the
screening protocol (ie. inspiratory CT and pulmonary function
testing) in our center, starting July 2007. This addition was
separately approved by the local ethical review board of the
University Medical Center Utrecht (approval 03-040/C). Written
informed consent was obtained from each participant.
Study population
The NELSON-trial enables valuable research into the early
stages of COPD, which is more difficult in clinical routine because
early COPD is not an indication for chest CT in our routine
practice. Participants were all current or former heavy smokers
meeting the inclusion criteria of the screening trial, as described
previously [22]. Briefly, participants were heavy smokers between
the ages of 50 and 75 year with at least 16.5 packyears of smoking
history who were also physically fit enough to undergo potential
surgery. For the present study we included a random sample of
266 male individuals who had lung function testing and a paired
inspiratory and expiratory CT scan obtained on the same day
between July 2007 and September 2008. This cohort is a
representative sample of the total screening population. The
comparison between our study population and the total screening
trial population is shown in Table 1. A flow diagram of the study is
shown in Figure 1.
CT scanning
Volumetric CT in inspiration and at end-expiration was
obtained from lung bases to lung apices after standardized
breathing instructions by a trained radiographer. CT images were
acquired with 1660.75 mm collimation (Brilliance 16P; Philips
Medical Systems, USA), and images with slice thickness of 1.0 mm
at 0.7 mm increment were reconstructed using a smooth kernel (B-
filter; Philips). Dose settings were adjusted to body weight: subjects
weighing 80 kg or less received 120 kVp at 30 mAs for the
inspiratory acquisition and 90 kVp at 20 mAs for the expiratory
acquisition. Subjects weighing over 80 kg received 140 kVp at
30 mAs for the inspiratory acquisition and 120 kVp at 20 mAs for
the expiratory acquisition.
Pulmonary function testing
Pulmonary function testing without bronchodilator administra-
tion was performed on the same day as CT imaging. Spirometry
was performed with ZAN equipment (ZAN Messgera¨te GmbH,
Oberthulba, Germany), according to the American Thoracic
Society and European Respiratory Society guidelines [23]. The
lung function testing included forced expiratory volume in the first
second (FEV1) and the ratio of FEV1 over forced vital capacity
(FEV1/FVC). The reference standard for COPD was a FEV1/
FVC ratio less 0.70 [4].
Visual evaluation of CT images
Eight observers with various levels of expertise in evaluating
chest CT images [24] participated in this study. The observers
Table 1. Comparison between the included subsample of participants and the total cohort of screening participants in the study
period between July 2007–September 2008.
Study populationa All screening participantsb
(N=266) (N=1,741)
Age in years
Mean 6 SD 62.565.0 62.665.4
CT emphysema (%)
Mean 6 SD 1.7463.34 1.6763.01
Median [P25–P75] 0.78 [0.40–1.58] 0.76 [0.39–1.49]
CT air trapping (%)
Mean 6 SD 84.465.9 84.166.5
Median [P25–P75] 84.9 [80.9–88.4] 84.7 [80.2–88.3]
Comparison using Mann-Whitney U test revealed no significant differences between the two groups.
adata in the randomly selected subsample of male participants;
bdata in the total group of male participants screened in the study period
doi:10.1371/journal.pone.0042227.t001
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were one specialized chest radiologist (P.A.J), one senior radiologist
(E.Th.S), one senior-resident in radiology with chest radiology
specialty (H.A.G), two junior residents in radiology (R.P.H.B,
M.A), one clinical research coordinator evaluating lung cancer
screening chest CT images (S.A.V), and two MDs performing
COPD research (F.M.H, O.M.M); see Table 2 for more detailed
information.
All CT images were anonymized and presented to the observers
in a randomized order on a 3D research workstation (iXviewer,
Image Sciences Institute, Utrecht, The Netherlands). For each
case, the paired inspiratory and expiratory CT scans were shown
alongside each other. The observers were able to view each scan
completely and in any direction, corresponding to clinical routine.
The observers were asked to judge whether lung function
impairment was present in the case presented (ie. COPD present
or absent), based on their evaluation of the presence and extent of
emphysema, air trapping, airway abnormalities or any other
finding on CT imaging. They were also provided with some basic
patient characteristics, similar as applied in the automated
evaluation (ie. age, body mass index, smoking status and smoking
history; see next paragraph). To closely resemble daily practice,
visual evaluation of the cases was performed without a prior
Figure 1. Flow diagram of the study. Flow diagram showing the selection of the study population from the total screening trial cohort. The index
test presented is for the observer with the highest positive predictive value.
doi:10.1371/journal.pone.0042227.g001
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consensus meeting. Each of the 266 cases was evaluated by all
eight observers. To study intraobserver agreement, a subset of 30
random cases was evaluated a second time by all observers.
Automated evaluation of CT images
COPD presence was automatically evaluated, using a CT
model that includes quantitative measures of CT emphysema and
CT air trapping, age, body mass index, smoking status and
smoking history. The model has previously been described in
detail elsewhere [21]. In summary, the predicted probability for
COPD presence was calculated using a regression equation (Prob-
abilityCOPD=211.400+0.9036*CT emphysema(log)+0.1519*CT air
trapping 20.0645*BMI+0.0083*packyears (20.7115 if former smok-
er). Based on the calculated probability, subjects were dichotomized as
either COPD subjects or non-COPD subjects according to an optimal
cut-off value [21].
Statistical Analyses
Kappa (k) values were calculated in order to assess intraobserver
and interobserver agreement. Agreement was classified as poor
when k was 0.20 or less, fair when between 0.21 and 0.40,
moderate when between 0.41 and 0.60, good when between 0.61
and 0.80, and very good when higher than 0.80 [25]. Both the
automated and the visual evaluation were compared to the
reference standard of pulmonary function testing, and diagnostic
performance was calculated in terms of the sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV)
and accuracy, all with 95% confidence intervals. Results are
presented separately for the less experienced and experienced
observers.
Diagnostic performance was compared between each observer
and the automated evaluation by the CT model [26].
All analyses were performed with SPSS Version 15.0 for
Windows (SPSS, Chicago, Illinois, USA). A p-value below 0.05
was considered statistically significant.
Results
Study population
Our study population consisted of 266 heavily smoking male
subjects with a mean 6 standard deviation age of 62.565.0 years.
Detailed study population characteristics are presented in Table 3.
Observer agreement in CT-based evaluation of COPD
presence
The intraobserver agreement ranged from a k-value of 0.28 to
0.68 (median 0.64) for the less experienced observers, and from
0.49 to 0.53 (median 0.49) for the experienced observers. The
interobserver agreement for the less experienced observers yielded
k-values between 0.18 and 0.55 (median 0.36). The interobserver
agreement for the experienced observers yielded k-values between
0.35 and 0.57 (median 0.40).
The agreement between each less experienced observer and the
automated CT model yielded k values between 0.12 and 0.30
(median 0.28). For the experienced observers this ranged between
0.20 and 0.35 (median 0.33). Results on the observer agreement
are listed in Table 4.
Table 2. Expertise levels and experience of the human observers.
Job Title Expertise levela Reading chest CTb (years)
Observer 1 MD researcher I 0
Observer 2 MD researcher I 2
Observer 3 Junior resident II 2
Observer 4 Junior resident II 2
Observer 5 Clinical research coordinator II 7
Observer 6 Senior resident IV 8
Observer 7 Senior radiologist V 34
Observer 8 Chest radiologist V 10
alevel of expertise based as on Reference [24]: I has knowledge and some skills, II acts under full supervision, III acts under limited supervision, IV acts without
supervision, V supervises and teaches;
bYears since the observer started reading and evaluating chest CT scans; Observer 1 to 5 were considered ‘less experienced observers’ and observer 6 to 8 were
considered ‘experienced observers’.
doi:10.1371/journal.pone.0042227.t002
Table 3. Characteristics of the 266 study participants.
Characteristic Values
Age, years [mean 6 SD] 62.565.0
BMI, kg/m2 [mean 6 SD] 26.863.4
Smoking status
Current smoker [n (%)] 135 (50.8)
Former smoker [n (%)] 131 (49.2)
Packyears, median [P25–P75] 38 [28–46]
FEV1, % predicted [mean 6 SD] 93.6617.0
FEV1/FVC, % [mean 6 SD] 69.369.2
Airflow limitation [n (%)]a 118 (44.4)
Mild obstruction [n (%)] 73 (27.4)
Moderate obstruction [n (%)] 40 (15.0)
Severe obstruction [n (%)] 5 (1.9)
aairflow limitation was defined as FEV1/FVC ratio less than 70% and classified as
mild (FEV1$80%), moderate (50%#FEV1,80%) and sever (FEV1,50%);
SD = Standard deviation; FEV1 = forced expiratory volume in the first second;
FEV1/FVC= ratio of FEV1 over forced vital capacity
doi:10.1371/journal.pone.0042227.t003
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Diagnostic performance for CT-based evaluation of
COPD presence
In our study population, 44.4% (118/266) of the subjects had
COPD according to the reference standard. The percentage of
subjects with suspected COPD after visual evaluation of the CT
images by the human observers ranged from 25.9% to 60.2%. The
accuracy of the less experienced observers ranged from 58.3% to
62.4%, and the positive predictive value ranged from 52.9% to
60.9%. For the experienced observers this was 64.7% to 73.3% for
the accuracy, and 64.6% to 74.7% for the positive predicted value.
The percentage of subjects with suspected COPD after
automated evaluation by the CT model was 38.0%. The
automated CT model had an accuracy of 74.1% and a positive
predicted value of 74.3%. Table 5 specifies the diagnostic
performance measures for each observer and for the automated
CT model.
Comparison between the automated evaluation by the CT
model and the visual evaluation by the human observers shows
that all but two observers had a significantly worse diagnostic
performance in either sensitivity or specificity, or both
(0.001,p,0.05). Only the specialized chest radiologist clearly
approached the diagnostic performance of the CT model
(p = 0.79), while a clear trend was seen for the other, less
experienced observer (p = 0.06).
Discussion
In this study we report the diagnostic performance of human
observers in identifying subjects with COPD using visual
evaluation of lung cancer screening chest CT scans. Their
performance was compared to the performance of automated
evaluation of CT images. Accuracy of visual evaluation for COPD
presence was modest, and the accuracy of the automated
evaluation was higher than that of the observers. Diagnostic
performance of the human observers seems to improve slightly
with level of expertise, and approaches that of the automated
model for the specialized chest radiologist. Nevertheless, intraob-
server and interobserver variation was substantial, even in the
most experienced observers. Our study demonstrates that
although CT images contain diagnostic information related to
COPD in a population with mainly early stages of disease, the
reliability and diagnostic accuracy of visual evaluation is limited
and certainly not better than automated evaluation.
The fairly low accuracy of visual evaluation for COPD presence
shows that human observers experience difficulty in judging which
lung abnormalities are functionally relevant. In addition, the
limited intraobserver and interobserver agreement found indicates
that human observers have their own subjective and inconsequent
understanding of what COPD would look like on CT (ie. what
type of abnormalities, and to what extent, will result in airflow
Table 4. Intra- and interobserver agreement for CT based identification of COPD.
Observer 1
Observer 1 0.64 Observer 2
Observer 2 0.39 0.28 Observer 3
Observer 3 0.49 0.32 0.68 Observer 4
Observer 4 0.25 0.18 0.38 0.68 Observer 5
Observer 5 0.46 0.28 0.55 0.33 0.53 Observer 6
Observer 6 0.55 0.35 0.36 0.32 0.48 0.49 Observer 7
Observer 7 0.53 0.31 0.48 0.43 0.55 0.57 0.49 Observer 8
Observer 8 0.30 0.35 0.32 0.25 0.35 0.35 0.40 0.53
Automated CT
Model
0.30 0.12 0.28 0.23 0.30 0.20 0.33 0.35
Data given are Kappa (k) values.
doi:10.1371/journal.pone.0042227.t004
Table 5. Diagnostic performance measures with 95%
confidence interval for CT-based evaluation of COPD
presence.
Sensitivity Specificity PPV NPV Accuracy
Observer 1 35.6 81.8 60.9 61.4 61.3
(29.8–41.4) (77.1–86.4) (55.0–66.7) (55.6–67.3) (55.4–67.1)
Observer 2 54.2 61.5 52.9 62.8 58.3
(48.3–60.2) (55.6–67.3) (46.9–58.9) (57.0–68.6) (52.3–64.2)
Observer 3 51.7 70.9 58.7 64.8 62.4
(45.7–57.7) (65.5–76.4) (52.7–64.6) (59.1–70.6) (56.6–68.2)
Observer 4 73.7 50.7 54.4 70.8 60.9
(68.4–79.0) (44.7–56.7) (48.4–60.4) (65.3–76.2) (55.0–66.8)
Observer 5 49.2 70.9 57.4 63.6 61.3
(43.1–55.2) (65.5–76.4) (51.5–63.4) (57.9–69.4) (55.4–67.1)
Median Obs 1–
5
51.7 70.9 57.4 63.6 61.3
(45.7–57.7) (65.5–76.4) (51.5–63.4) (57.9–69.4) (55.4–67.1)
Observer 6 44.9 80.4 64.6 64.7 64.7
(38.9–50.9) (75.6–85.2) (58.9–70.4) (58.9–70.4) (58.9–70.4)
Observer 7 50.8 78.4 65.2 66.7 66.2
(44.8–56.9) (73.4–83.3) (59.5–70.9) (61.0–72.3) (60.5–71.9)
Observer 8 60.2 83.8 74.7 72.5 73.3
(54.3–66.1) (79.4–88.2) (69.5–80.0) (67.2–77.9) (68.0–78.6)
Median Obs 6–
8
50.8 80.4 65.2 66.7 66.2
(44.8–56.9) (75.6–85.2) (59.5–70.9) (61.0–72.3) (60.5–71.9)
Automated CT
Model
63.6 82.4 74.3 73.9 74.1
(57.8–69.3) (77.9–87.0) (69.0–79.5) (68.7–79.2) (68.8–79.3)
Data given are percentages.
PPV positive predicted value; NPV negative predictive value
doi:10.1371/journal.pone.0042227.t005
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obstruction and abnormal lung function). This finding is in line
with previous literature that has shown that visual evaluation of
emphysema, air trapping and airway wall thickening are prone to
considerable interobserver variability [27–31]. This, together with
the modest diagnostic accuracy, has clinical implications: the
extensive and increasing use of CT imaging [32], combined with
the commendable practice of radiologists to report all imaging
findings, including the incidental and unrequested ones, may lead
to an increase in subjects who are wrongfully stigmatized based on
the presence of COPD-related abnormalities on CT. Consequent-
ly, our study urges radiologist to remain cautious in interpreting
these abnormalities and in reporting previously unknown disease.
Whenever COPD is suspected based on CT findings, confirmatory
lung function testing is required and should always be suggested.
Since CT-based lung cancer screening in heavy smokers is now
recommended in the US [33,34] the chances to detect early
COPD in high-risk subjects using screening CT images are
increasing. At this stage, better understanding of functionally
relevant CT abnormalities and improvement of observer agree-
ment should be sought, which may lead to improved accuracy. On
the other hand, identification of COPD can be based on
automated evaluation using quantitative CT analysis, which we
believe will become more important than that of visual evaluation;
it is fast and inexpensive and the basic CT model, which at this
stage includes only simple lung density measures and few patient
characteristics, already performs better than the human observers.
Its performance is approached only by the specialized chest
radiologist, and it is unlikely that in daily practice the large amount
of lung cancer screening CT scans will be reviewed by a
specialized chest radiologist. Nevertheless, the quantitative ap-
proach needs to be further validated and improved, and clinical
use might require more standardized CT operating procedures to
limit differences between CT scanners and differences in breath
hold procedures.
Our study is of importance since it addresses a common clinical
problem, related to a disease with major healthcare impact. The
main strengths are that we have used a representative sample of
CT readers with various levels of expertise, and closely resembled
clinical practice with 3D inspiratory and expiratory CT data and
some clinical information. Also, we were able to provide data on a
substantial number of subjects with early stages of COPD who are
difficult to obtain in routine practice.
Our study has limitations. Firstly, spirometry was performed
without administration of a bronchodilator, which is recom-
mended to exclude asthma. However, we believe it is unlikely that
this has significantly influenced the results because the prevalence
of asthma in men between the ages of 50 and 75 years is only
approximately 2% in the general population of the Netherlands
[35], and our study population comprised only heavy smokers.
Secondly, our study was limited to male subjects. This may limit
the generalizability of our findings. Thirdly, our study evaluated
functionally relevant lung abnormalities at the time of imaging.
Given the cross-sectional nature of our study we cannot comment
on whether observers identified subclinical abnormalities that may
lead to abnormal lung function in the future. Lastly, we were
unable to include more than one or two observers at each level of
expertise, which impedes analysis within a group of similar
experienced observers. Nevertheless, our results are based on a
fairly large group of observers subdivided into a less experienced
and experienced subgroup.
In conclusion, this study reports modest diagnostic accuracy of
human observers in the visual evaluation for COPD presence on
volumetric inspiratory and expiratory CT images in heavy
smokers. Moreover, visual evaluation for COPD presence is
associated with substantial observer variation. Our findings suggest
that visual evaluation of CT scans for COPD presence is of limited
diagnostic value, while there may be a role for automated
evaluation. This may be important for the additional identification
of COPD subjects in a CT-based lung cancer screening setting.
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